According to Zhitong Finance App, Fuson Pharmaceutical (01652.HK) announced that the self-developed “nicardipine hydrochloride injection” developed by Henan Fuson Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Group, has submitted an application for consistent evaluation of the quality and efficacy of generic drugs to the China National Drug Administration and has been accepted. The indications for nicardipine hydrochloride injection are emergency treatment of abnormal high blood pressure during surgery and emergency cases of high blood pressure.

Zhitongcaijing · 10/15 14:09
According to Zhitong Finance App, Fuson Pharmaceutical (01652.HK) announced that the self-developed “nicardipine hydrochloride injection” developed by Henan Fuson Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the Group, has submitted an application for consistent evaluation of the quality and efficacy of generic drugs to the China National Drug Administration and has been accepted. The indications for nicardipine hydrochloride injection are emergency treatment of abnormal high blood pressure during surgery and emergency cases of high blood pressure.